3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
36
Neoplasm Metastasis
10
Neoplasms
7
Brain Neoplasms
4
Triple Negative Breast Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Advanced Malignant Solid Tumors
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Salivary Gland Neoplasms
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Meningioma
1
Malignant Female Reproductive System Neoplasm
1
Interventions
Magnetic Resonance Spectroscopy
16
Hydroxyurea
7
Everolimus
7
Bevacizumab
7
lutetium Lu 177 dotatate
6
gallium Ga 68 dotatate
6
Proton Therapy
6
Specimen Handling
5
pembrolizumab
4
Surgical Procedures, Operative
4
Radiosurgery
4
Imatinib Mesylate
4
Cyclophosphamide
4
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
4
aldesleukin
3
abemaciclib
3
Tranexamic Acid
3
Temozolomide
3
Sunitinib
3
Sodium Chloride
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Nivolumab
3
Ga(III)-DOTATOC
3
90Y-octreotide, DOTA-Tyr(3)-
3
vistusertib
2
trametinib
2
ribociclib
2
fludarabine
2
arginyllysine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Meningioma
×
neratinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled